Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;30(9):2381-7.
doi: 10.1007/s10103-014-1703-4. Epub 2015 Jan 7.

Targeted photodynamic therapy in head and neck squamous cell carcinoma: heading into the future

Sophie Marchal  1   2   3 , Gilles Dolivet  4   5   6 , Henri-Pierre Lassalle  4   5   7 , François Guillemin  4   5   6 , Lina Bezdetnaya  4   5   7
Affiliations
Review

Targeted photodynamic therapy in head and neck squamous cell carcinoma: heading into the future

Sophie Marchal et al. Lasers Med Sci. 2015 Dec.

Abstract

The aim of this article is to give an insight into the future of photodynamic therapy (PDT) in head and neck squamous cell carcinoma (HNSCC). Through the combination of a photosensitizing agent with light and oxygen, PDT produces highly cytotoxic reactive oxygen species leading to selective tumor eradication. PDT is an attractive treatment for focal therapy of localized tumors, especially in the case of unresectable tumors. In HNSCC, over 1500 patients have been treated by PDT, and the majority of them responded quite favorably to this treatment. However, the non-negligible photosensitization of healthy tissue is a major limitation for the clinical application of PDT. Improvement in tumor selectivity is the main challenge that can be taken up by the use of a new generation of photosensitizing nanoparticles. Passive targeting, by using functionalised nanocarriers to target to overexpressed transmembrane receptors afford attractive solutions. To this day, epidermal growth factor receptor (EGFR) remains the only validated molecular target for HNSCC, and photosensitizer immunoconjugates to EGFR have been developed for the intracellular delivery of photosensitizing agents. Depending on coordinated research between biomarkers, specific ligands, and photosensitizers, similar approaches could be rapidly developed. In addition, some photosensitizers hold high fluorescence yield and therefore could emerge as theranostic agents.

Keywords: Active targeting; Head and neck squamous cell carcinoma; Nanoparticles; Passive targeting; Photodynamic therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Curr Pharm Biotechnol. 2007 Dec;8(6):362-72 - PubMed
    1. J Surg Res. 2014 Dec;192(2):235-41 - PubMed
    1. Mol Pharm. 2011 Dec 5;8(6):2101-41 - PubMed
    1. Photochem Photobiol. 2012 Mar-Apr;88(2):432-9 - PubMed
    1. Lasers Surg Med. 2011 Aug;43(6):463-9 - PubMed

MeSH terms

LinkOut - more resources